TScan Therapeutics posts new JP Morgan presentation

TScan Therapeutics, Inc. furnished a new corporate presentation that it plans to use in meetings during the 44th Annual J.P.

Rhea-AI Filing Summary

TScan Therapeutics, Inc. furnished a new corporate presentation that it plans to use in meetings during the 44th Annual J.P. Morgan Healthcare Conference. The materials are provided as Exhibit 99.1 and are also available in the investor relations section of the company’s website. The presentation is being furnished under a current report on Form 8-K, meaning it is not treated as filed for liability purposes and is not automatically incorporated into other securities law filings unless specifically referenced.

8-K Event Classification

Item 7.01 — Regulation FD Disclosure

1 item

Item 7.01 Regulation FD Disclosure Disclosure

Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did TScan Therapeutics (TCRX) disclose in this Form 8-K?

TScan Therapeutics, Inc. disclosed that it has made available a corporate presentation to be used in meetings around the 44th Annual J.P. Morgan Healthcare Conference, and furnished this presentation as Exhibit 99.1.

Where can investors find the new TScan Therapeutics (TCRX) corporate presentation?

The corporate presentation is furnished as Exhibit 99.1 to the Form 8-K and is also available on the investor relations section of TScan Therapeutics’ website at https://ir.tscan.com.

Is the TScan Therapeutics (TCRX) corporate presentation considered filed with the SEC?

No. The information under Item 7.01, including Exhibit 99.1, is being furnished, not filed, so it is not subject to Section 18 of the Exchange Act and is not incorporated into other filings unless specifically referenced.

What event is associated with the new TScan Therapeutics (TCRX) presentation?

The presentation is intended for potential meetings coinciding with the 44th Annual J.P. Morgan Healthcare Conference during the week of January 12, 2026.

Does TScan Therapeutics (TCRX) have an obligation to update the furnished presentation?

The company states it undertakes no obligation to update, supplement or amend the material attached as Exhibit 99.1.

Which exhibit numbers are included in this TScan Therapeutics (TCRX) Form 8-K?

The Form 8-K includes Exhibit 99.1, the corporate presentation, and Exhibit 104, the cover page interactive data embedded within the Inline XBRL document.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 01/12/2026 - 07:30 AM Learn about SEC filing dates

false 0001783328 0001783328 2026-01-12 2026-01-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): January 12, 2026

TSCAN THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-40603		82-5282075
(State or other jurisdiction of incorporation or organization)		(Commission File Number)		(I.R.S. Employer Identification No.)

830 Winter Street, Waltham, Massachusetts		02451
(Address of Principal Executive Offices)		(Zip Code)

(857) 399-9500

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Voting Common stock, par value $0.0001 per share		TCRX		The Nasdaq Global Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 7.01 Regulation FD Disclosure.

On January 12, 2026, TScan Therapeutics, Inc. (the “Company”) made available a corporate presentation (the “Corporate Presentation”) that it intends to use in potential meetings that coincide with the 44th Annual J.P. Morgan Healthcare Conference (the “Conference”) during the week of January 12, 2026, including meetings with investors, analysts, and other Conference participants. A copy of the Corporate Presentation is furnished as Exhibit 99.1 hereto. The Corporate Presentation will also be available on the investor relations section of the Company’s website at https://ir.tscan.com. Information contained on the Company’s website is not incorporated by reference into this Current Report on Form 8-K, and you should not consider any information on, or that can be accessed from, the Company’s website as part of this Current Report on Form 8-K.

The information under this Item 7.01, including Exhibit 99.1 hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing. The Company undertakes no obligation to update, supplement or amend the material attached hereto as Exhibit 99.1.

Item 9.01. Exhibits

(d) Exhibits

Exhibit No.		Description
99.1		Corporate Presentation, furnished herewith.
104		Cover Page Interactive Data (embedded within the Inline XBRL document).

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				TScan Therapeutics, Inc.
Date: January 12, 2026				By:		/s/ Gavin MacBeath
						Gavin MacBeath
						Chief Executive Officer